Shire: Pipeline, Products, Performance, Potential

Shire: Pipeline, Products, Performance, Potential

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

In the last five years, Shire has spent over US$8 billion on acquisitions which have seen the company considerably expand its global presence and areas of interest. Most importantly, these acquisitions have added four key products to a portfolio that was becoming dated and facing threats to its intellectual property. The addition of Vyvanse (from New River Pharmaceuticals) will help further cement the company's position as a leader in the treatment of attention deficit hyperactivity disorder (ADHD; traditionally Shire's strongest field). Meanwhile, the additions of Replagal and Elaprase (both from Transkaryotic Therapeutics) have expanded Shire's specialty centred business into the treatment of genetic diseases.

During 2006, Shire reached a key settlement with Barr Pharmaceuticals. The two companies had been involved in patent litigation over Adderall XR, Shire's top-selling product, which has patent protection until 2019. The agreement between the two companies allows Barr to launch its generic Adderall XR product ten years prior to patent expiry, however, it should prevent further patent challenges and limit generic competition until 2019. A key component of this agreement was the granting of a licence to Shire to begin developing Duramed Pharmaceuticals' (a subsidiary of Barr) new oral contraceptive, Seasonique, as well as five other products, which utilise Duramed's transvaginal ring technology. With this licence, Shire could begin to move into yet another new key area of interest, women's health, further expanding what was previously a very limited product portfolio.

Therefore, Shire has radically overhauled its corporate profile and expanded the scope of its operations. However, in July 2008, the company announced it was terminating commercialisation of Dynepo (epoetin delta), its novel anaemia treatment, after less than a year on the market. According to the company, changes in the external environment, including the launch of several biosimilars at lower prices, have proved challenging for Dynepo. Espicom originally forecasted peak sales of US$750 million for the product based on market size.

Contents

• Executive Summary
  • A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
• Therapeutic Area Focus
  • Key product analysis and forecasting
• Central Nervous System
  • Adderall/Adderall XR (mixed amphetamine salts)
  • Daytrana (methylphenidate)
  • Reminyl (galantamine)
  • Vyvanse (lisdexamphetamine dimesylate)
• Human Genetic Therapies
  • Elaprase (idursulfase)
  • Replagal (agalsidase)
• Gastrointestinal
  • Lialda/Mezavant (mesalamine)
  • Pentasa (mesalamine)
• Operational Data
  • A wealth of background and detail
  • A full 5-year financial performance assessment
  • Key corporate events
  • Key agreements
  • Infrastructure
  • Subsidiaries and joint ventures

Related products